# Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

> **NCT06734533** · — · RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- HR+ Breast Cancer

## Interventions

- **OTHER:** Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc

## Key facts

- **NCT ID:** NCT06734533
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734533, "Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06734533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*